News | April 28, 2026
From losses to lift-off: Astec gains ground in Q4 FY26
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
Subscribe To Our Newsletter & Stay Updated
